middle.news
Noxopharm gains FDA support for SOF-SKN lupus trial plan
8:15am on Thursday 8th of October, 2026 AEDT
•
Biotechnology
Read Story
Noxopharm gains FDA support for SOF-SKN lupus trial plan
8:15am on Thursday 8th of October, 2026 AEDT
Key Points
Supportive FDA pre-IND feedback on Phase II design
Chemical manufacturing strategy received particular backing
Future US IND submission remains in preparation
Phase II trial targeted for H1 calendar 2028
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE